Business

Drugged Returns

Advertisement

Drugged Returns
info_icon
Annual US sales
FluoxetineDr Reddy’s share fell from 50 to 30 per cent in three years$1.8 billion
CarbamazepineSun Pharma’s one per cent share is due to its focus on antidepressants and lack of scale$70 million
CitalopramDr Reddy’s share of 15 per cent is
limited due to competition and the presence of larger MNCs
$1.4 billion
MetforminRanbaxy’s share of two per cent is because it entered in 2005$1 billion
EnalaprilDespite being early entrants, Ranbaxy and Wockhardt couldn't garner more than 10 per cent share each$500 million
CaptoprilWockhardt has a negligible share as it was a late entrant$150 million

Advertisement

Tags

    Advertisement

    Advertisement

    Advertisement

    Advertisement

    Advertisement

    Advertisement